Sitemap
- Home
- Rare Blood Disorders
- Other topics
- Products
- Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
- Fc Fusion allows ALPROLIX® to mirror the pathway followed by endogenous factor IX
- ALPROLIX® is the only factor IX to utilize half-life extension with Fc Fusion technology
- Bleed reduction observed in real-world SHL switches1
- ALPROLIX® has a decade of experience your patients can trust1
- Many patients with hemophilia B may adjust their management approach over time to fit their needs1,2
- Extravascular distribution
- ALPROLIX® prophylaxis has extended dosing vs SHLs that helps reduce the treatment burden1,2
- ALPROLIX® offers effective hemostatic control for both major and minor surgeries1
- Demonstrated safety profile for ALPROLIX® for patients across all ages and settings1
- The behavior of factor IX in the body is complex
- On-demand dosing with ALPROLIX® can be used to control your patients' bleeding episodes1
- ALPROLIX® offers hemostatic control for both major and minor surgeries1
- ALPROLIX® prophylaxis offers bleed and joint bleed protection1*
- Efficacy on-demand
- Contact a Representative
- A decade of dedication: our unwavering commitment to you and your patients
- ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]
- HCP resources
- Pediatric Study - Safety
- Pediatric Study - Results
- Dosing regimen
- Dosing Calculator
- Resources for your patients
- Contact a Representative
- Mechanism of half-life extension (MOE)
- Adult & Adolescent Study - Pharmacokinetics
- Pediatric Study - Trial Design
- Adult & Adolescent Study - Efficacy
- Clinical Cases
- Hemophilia A Case Study: Otis
- Hemophilia A Case Study: Noah
- Hemophilia A Case Study: Peter
- Pediatric Study - Pharmacokinetics
- About Hemophilia A
- Adult & Adolescent Study - Safety
- Surgical Data in Patients with Hemophilia A
- Surgical Data in Patients with Hemophilia A
- Adult & Adolescent Study - Trial Design
- Beyfortus® (nirsevimab-alip) injection
- Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
- Therapeutic Areas
- Articles
- Resources
- Sitemap
